We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at ...
A new study illustrates the research journey behind the creation of Monteloeder's latest nootropic formulation Mindrevivetm.
JPMorgan analyst Anupam Rama established a $9 December 2025 price target on shares of Sage Therapeutics (SAGE) while keeping a Neutral rating ...
Carbon capture and storage is a means by which carbon dioxide gas is stored underground, per Reuters. The CO2 is often ...
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
Beer proudly presents “Making Waves,” a new film chronicling the extraordinary career of professional surfer Lakey ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...
Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
Douglas Tsao; Analyst; H.C. Wainwright & Co., L.L.C.
Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...